The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. Danazol may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Primidone. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The metabolism of Paricalcitol can be increased when combined with Phenytoin. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. Indapamide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The metabolism of Paricalcitol can be increased when combined with Nevirapine. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Clemastine. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant.